Brief: Valbiotis: Expansion Of Application For Valedia To Include NASH Prevention

Valbiotis SA

12/11/2018 06:39

Nov 12 (Reuters) - VALBIOTIS SAS  ALVAL.PA :
    * VALBIOTIS ANNOUNCES EXPANSION OF APPLICATION FOR VALEDIA
TO
INCLUDE NASH PREVENTION
    * NEW RESULTS DEMONSTRATE CLINICAL POTENTIAL OF VALEDIA FOR
NASH
RISK REDUCTION.
    * STUDIES ON VALEDIA SHOW COMPLETE REVERSION OF HEPATIC
STEATOSIS
IN AN IN VIVO PRECLINICAL MODEL
    * PHASE II CLINICAL DEVELOPMENT OF VALEDIA FOR NASH RISK
REDUCTION
WILL START WITH A PHASE IIA RANDOMIZED WITH PLANNED LAUNCH IN
2019 IN A TARGET POPULATION WITH NAFL
    * BASED ON THESE RESULTS, CO PLANS TO LAUNCH PHASE II
CLINICAL
STUDIES IN ADDITION TO ONGOING STUDIES FOR THE RISK REDUCTION OF
TYPE 2 DIABETES

Source text for Eikon:  ID:nBw3mHmWna 
Further company coverage:  ALVAL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))